Unal, UlkuGov, Esra2025-01-062025-01-0620230735-79071532-419210.1080/07357907.2023.22556722-s2.0-85171652106https://doi.org/10.1080/07357907.2023.2255672https://hdl.handle.net/20.500.14669/2087This study aimed to reveal the drug-repurposing candidates for colorectal cancer (CRC) via drug-repurposing methods and network biology approaches. A novel, differentially co-expressed, highly interconnected, and co-regulated prognostic gene module was identified for CRC. Based on the gene module, polyethylene glycol (PEG), gallic acid, pyrazole, cordycepin, phenothiazine, pantoprazole, cysteamine, indisulam, valinomycin, trametinib, BRD-K81473043, AZD8055, dovitinib, BRD-A17065207, and tyrphostin AG1478 presented as drugs and small molecule candidates previously studied in the CRC. Lornoxicam, suxamethonium, oprelvekin, sirukumab, levetiracetam, sulpiride, NVP-TAE684, AS605240, 480743.cdx, HDAC6 inhibitor ISOX, BRD-K03829970, and L-6307 are proposed as novel drugs and small molecule candidates for CRC.eninfo:eu-repo/semantics/openAccessColorectal cancercomputational systems biologybioinformaticsdrug repurposingcandidate drugsArticle733837682113Q371341WOS:001069407000001Q3